13/01/2026
๐ฃ๐๐๐ ๐๐ผ ๐ฐ๐ผ๐ป๐๐ถ๐ฑ๐ฒ๐ฟ ๐๐ผ๐ฟ๐ฎ๐๐ถ๐ฑ๐ฒ๐ป๐ถ๐ฏ ๐ณ๐ผ๐ฟ ๐ฃ๐๐ฆ ๐น๐ถ๐๐๐ถ๐ป๐ด โ ๐ ๐ฎ๐ฟ๐ฐ๐ต ๐ฎ๐ฌ๐ฎ๐ฒ
๐ฆ๐๐ฏ๐บ๐ถ๐๐๐ถ๐ผ๐ป๐ ๐ฐ๐น๐ผ๐๐ฒ: ๐ฎ๐ญ ๐๐ฎ๐ป๐๐ฎ๐ฟ๐ ๐ฎ๐ฌ๐ฎ๐ฒ
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider vorasidenib for potential PBS listing at its March 2026 meeting.
For people living with IDH-mutant glioma, access to effective treatments can be life-changing. Personal perspectives help PBAC better understand the real-world impact of brain cancer and the importance of timely, affordable access to new therapies.
The NRF encourages patients, carers, and families to contribute.
If you or someone you support has experience with vorasidenibโor would benefit from access to itโyour insight can help inform this decision!
https://shorturl.at/W5YbP